Meeting
2018 ASCO Annual Meeting
Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.
Authors
Tomomi Kashiwada
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Tomomi Kashiwada , Hiroshi Saeki , Yoshikazu Uenosono , Akitaka Makiyama , Masaaki Iwatsuki , Yukiya Narita , Hironaga Satake , Yoshiko Matsuda , Hideto Sonoda , Eiji Oki , Yoshihiko Maehara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4038)
DOI
10.1200/JCO.2018.36.15_suppl.4038
Abstract #
4038
Poster Bd #
227
Abstract Disclosures
Similar Posters
Poster
2015 Breast Cancer Symposium
Dual inhibition of DNA double strand break (DSB) repair and PI3K pathway with BEZ235 (BEZ) to sensitize refractory metastatic (met) triple negative breast cancer (TNBC) to nab paclitaxel/cisplatin (pac/cis) in a patient with an exceptional response (ExRx).
First Author: Joyce O'Shaughnessy
Poster
2013 ASCO Annual Meeting
Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.
First Author: Florian Lordick
Poster
2013 Gastrointestinal Cancers Symposium
A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.
First Author: Yung-Jue Bang
Poster
2023 ASCO Annual Meeting
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
First Author: Se-Hoon Lee